RT-PCR Technique
FOR IMMEDIATE RELEASE
Universal Therapeutics to offer second Covid-19 test
This test is based on a one-step highly accurate RT-PCR technique
Kuala Lumpur, Malaysia, 1st December 2020
A second, more comprehensive test for the detection of Covid-19 is available to health care providers in Singapore, Malaysia, Thailand, United Arab Emirates, Kenya, and Ghana.
Beijing Hotgen Biotech Co., Ltd. has announced the appointment of Universal Therapeutics as Main Distributor for their RT- PCR COVID-19 Nucleic Acid Test Kit (PCR-Fluorescent Probe Method).
This is the second Covid-19 test developed by Bejing Hotgen, which also recently selected Universal Therapeutics to be its exclusive distributor for its Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) rapid test kit.
The RNA PCR COVID-19 Nucleic Acid Test Kit is the gold standard for the detection of novel Coronavirus,” said Mr. Sidney Soares, Deputy Chief Executive Officer of Universal Therapeutics. “It detects Covid-19 through a one-step RT-PCR amplification process that identifies the virus in nasopharyngeal swabs, oropharyngeal swabs, and bronchoalveolar lavage fluids. It produces a result in as little as 120 minutes.”
The test is particularly effective for diagnosing the novel Coronavirus in suspected pneumonia patients, suspected clustering cases, and others requiring differential diagnosis.
It is expected that test kits will be available for orders from the date of this news release.
To obtain a brochure and summary data Government bodies, medical institutions and health care providers are urged to contact their offices or visit https://www.Universal-Therapeutics.com for further information.
About Universal Therapeutics:
Universal Therapeutics is a multinational pharmaceutical and biotech company based in Kuala Lumpur, Malaysia. The company’s businesses include manufacturing, distribution and white label production of pharmaceutical products, medical supplies, and PPEs in Asia and throughout the world.
Universal Therapeutics distribute nitrile gloves; three-ply face masks; KN95 and N95 masks; “HotGen Covid-19 RNA PCR” tests and “HotGen Novel Corona virus 2019-nCoV Antigen (Colloidal Gold) – 15 Minutes Rapid” tests to wholesalers, medical institutions, and government organizations. Their products comply with World Health Organization (WHO) guidelines and are accredited and approved by various health ministries as safe for human use.
Subject to regulatory and safety approval, Universal Therapeutics has also been chosen to distribute Covid-19 vaccinations – in partnership with Beijing HotGen Biotech Co. Ltd.
(688068:CH) – by China National Pharmaceutical Group Corporation (Sinopharm).
For more information:
Samuel David Chai
Chief Commercial Officer
Office: +60 3 9213 0318
Email: GroupPR@Universal-Therapeutics.com
Website: www.Universal-Therapeutics.com